REGN Regeneron Pharmaceuticals Inc

987.31

6.74 (0.69%)

Last Updated: 16:20:21

Delayed by 15 minutes

Share Name	Share Symbol	Market	Type
Regeneron Pharmaceuticals Inc	NASDAQ:REGN	NASDAQ	Common Stock

	Price Change	% Change	Share Price	Bid Price	Offer Price	High Price	Low Price	Open Price	Shares Traded	Last Trade
	6.74	0.69%	987.31	987.33	987.91	988.77	983.00	984.04	54,744	16:20:21

Regeneron Antibody Cocktail Is First FDA-Approved Ebola Treatment

14/10/2020 11:40pm

Dow Jones News

Regeneron Pharmaceuticals (NASDAQ:REGN)
Historical Stock Chart

From May 2019 to May 2024

Click Here for more Regeneron Pharmaceuticals Charts.

   By Josh Beckerman

A Regeneron Pharmaceuticals Inc. antibody cocktail has become the first treatment for the Ebola virus approved by the U.S. Food and Drug Administration.

The treatment, Inmazeb, is also known as REGN-EB3. It includes atoltivimab, maftivimab and odesivimab-ebgn.

The FDA said "today's action demonstrates the FDA's ongoing commitment to responding to public health threats--both domestically and abroad--on the basis of science and data."

Regeneron shares were up 0.6% after hours at $604.62.

Write to Josh Beckerman at josh.beckerman@wsj.com

(END) Dow Jones Newswires

October 14, 2020 18:25 ET (22:25 GMT)